The human complement factor H protein family consists of the complement and immune regulators factor H, the factor H-like protein 1(FHL-1) and five factor H-related proteins (CFHR-1 to -5). Members of the H-related protein family are exclusively composed of individually folded protein domains, termed short consensus repeats (SCRs) or complement control modules. The genes of this family have been located in human chromosome 1q32, which is known as the regulators of complement activation (RCA) gene clusters. Complement factor H-related protein 1 (CFHR1) is a 43 kDa, secreted member of the factor H family of glycoproteins. It is produced by hepatocytes and circulates as two differentially glycosylated isoforms (37 kDa and 43 kDa). Complement Factor H-related 2 (CFHR2) is synthesized in the liver and secreted into plasma. It may be involved in complement regulation. CFHR2 can also be associated with lipoproteins and may play a role in lipid metabolism. CFHR-5 has been identified initially as a universal component of complement deposits, and detected in glomerular immune deposits. The pattern of deposits is similar to other complement components, suggesting that CFHR-5 may play a role in complement activation and regulation. It is synthesized in the liver and consists of 9 SCRs. CFHR-5 exhibits similar characteristics as those of factor H in heparin binding, CRP binding, and lipoprotein association. Weak factor I-dependent cofactor activity for C3b cleavage has also been observed.
Citations
Publication ()
Have you cited DCABH-201836 in a publication? Let us know and earn a reward for your research.
My Review for Anti-CFHR2 monoclonal antibody, clone 621622
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
